-
Valeant Pharmaceuticals International et al v. Actavis Laboratories FL, Inc. et al DC CAFC
- 1:18-cv-01288
- D. Del.
- Judge: Leonard P. Stark
- Filed: 08/22/2018
- Closed: 10/28/2019
- Latest Docket Entry: 02/14/2022
- PACER
3
Plaintiffs
4
Defendants
1
Accused
Product
6
Patents-in-Suit
433
Days in
Litigation
-
Valeant Pharmaceuticals International et al v. Actavis Laboratories FL, Inc. et al DC CAFC
- 1:18-cv-01288
- D. Del.
- Judge: Leonard P. Stark
- Filed: 08/22/2018
- Closed: 10/28/2019
- Latest Docket Entry: 02/14/2022
- PACER
Causes of Action
Infringement
Willful Patent Infringement
Market Sector
Biotech and Pharma
Court
Assigned Judge
Outcome Summary
Patent Information
-
Infringement
Actavis Laboratories FL Incorporated
- 6 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Version of Uceris | US 10,052,286 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,064,878 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,105,374 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,143,698 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,154,964 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,172,799 B1 | All Asserted Claims |
No infringement
Entry 161
|
Actavis Pharma Incorporated
- 6 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Version of Uceris | US 10,052,286 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,064,878 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,105,374 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,143,698 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,154,964 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,172,799 B1 | All Asserted Claims |
No infringement
Entry 161
|
Teva Pharmaceutical Industries Limited
- 6 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Version of Uceris | US 10,052,286 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,064,878 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,105,374 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,143,698 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,154,964 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,172,799 B1 | All Asserted Claims |
No infringement
Entry 161
|
Teva Pharmaceuticals USA, Inc.
- 6 Details
Accused Product | Patent # | Claim # | Outcome |
---|---|---|---|
Generic Version of Uceris | US 10,052,286 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,064,878 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,105,374 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,143,698 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,154,964 B2 | All Asserted Claims |
No infringement
Entry 161
|
Generic Version of Uceris | US 10,172,799 B1 | All Asserted Claims |
No infringement
Entry 161
|